Policy | June 28, 2022
R&D key for the growth of nation: Dr. Mandaviya
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
First and only PARP inhibitor to improve invasive disease-free survival in patients
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Subscribe To Our Newsletter & Stay Updated
